Trial Information

Summary: Compassionate Treatment of Malignant Neuroendocrine Tumors with Radioactive MIBG

The purpose of this research study is to evaluate the effectiveness of using a radioactive chemical known as metaiodobenzylguanidine (MIBG) to treat patients with malignant pheochromocytoma, which may lower the patient's need for antihypertensive medication and reduce the size of their tumors.

Patient Inclusion/Exclusion Criteria:

- At least 18 years of age - Diagnosed with malignant pheochromocytomas that are inoperable (incurable by surgery) or with metastases (cancer that has spread far from the adrenal gland)
- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 2, 2008 at 2:50:44 PM